Tactile Systems Technology, Inc. Q1 2026 Earnings Call Summary

Tactile Systems Technology, Inc. Q1 2026 Earnings Call Summary - Moby

Operational Execution and Strategic Growth Drivers

Revenue growth of 23% was driven by a fully resourced sales organization and a shift from capacity building to territory productivity and operating leverage. Lymphedema performance benefited from aligning advanced pump documentation with the Medicare National Coverage Determination (NCD), creating a more direct clinical pathway for Flexitouch. The company demonstrated operational agility by accelerating the launch of an AI-enabled prior authorization module to meet new Medicare fee-for-service requirements ahead of schedule. Airway clearance growth of 22% was supported by deep C-suite relationships with top respiratory DMEs and consistent account manager continuity. The acquisition of Lymphotech marks a strategic pivot from a product-centric company to an integrated solutions leader covering the full continuum of lymphatic care. Management attributed margin expansion to structural enhancements, including lower manufacturing costs and improved collection efficiencies rather than temporary cost-cutting.

2026 Outlook and Innovation Roadmap

Updated revenue guidance of $360 million to $368 million reflects the inclusion of Lymphotech and increased confidence in commercial execution despite early Medicare prior authorization variability. The next-generation AffloVest is on track for a 2026 commercial launch, featuring weight reduction and digital connectivity to target the winter respiratory season. Management expects the VA channel to become a more meaningful, stable contributor over time as expanded field teams deepen local system navigation. The product roadmap for 2027 includes Flexitouch enhancements such as a new controller, reduced hosing, and remote functionality via the Kylie mobile application. Guidance assumes airway clearance will grow modestly faster than lymphedema, with both segments expected to fall within the 9% to 12% total growth range.

Strategic Risks and Non-Recurring Items

Early implementation of Medicare prior authorization has shown administrative variability across different Medicare Administrative Contractors (MACs), leading to a cautious near-term outlook. The Lymphotech acquisition includes participation in federal LIGHT and GUIDE programs, providing over $290 million in potential research funding for lymphatic therapeutics. Operating expense guidance was adjusted upward to 10% to 12% growth to account for one-time acquisition and legal-related costs. A slight order acceleration occurred in Q1 for patient benefit to avoid resubmission under new April 13 Medicare prior authorization rules.

Story Continues

Q&A Session Highlights

Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.

Impact of Medicare prior authorization on Q2 and Q3 cadence

Management expects a lighter step-up in Q2 followed by a larger normalization in Q3 as the new prior authorization process settles. The company is actively monitoring inconsistent denial rates between different MACs, which they view as a temporary administrative hurdle rather than a long-term risk.

Strategic value and revenue contribution of Lymphotech acquisition

Current revenue contribution is primarily from service-based federal grants, which carry lower margins than the core business. Long-term value lies in R&D for personalized garments using bioimpedance and securing CPT codes for 3D diagnostic measurements.

Competitive dynamics with new bronchiectasis pharmaceutical treatments

Management views new drugs as a 'category lift' that increases disease awareness rather than a competitive threat. Pharmaceuticals address inflammation but do not replace the mechanical need for airway clearance to disrupt the 'vicious vortex' of mucus and infection.

One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here.

View Comments